You are here

  • Home
  • Archive
  • Volume 15, Issue 3
  • Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined
  1. David Gonzales
  1. Correspondence to David Gonzales
    Senior Researcher and Co-Director, Smoking Cessation Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, CR 115, Portland, OR 97239, USA; gonzales{at}ohsu.edu

https://doi.org/10.1136/ebm1047

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on:

    1. Piper ME,
    2. Smith SS,
    3. Schlam TR,
    4. et al
    . A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009;66:1253–62.
    OpenUrlCrossRefPubMedWeb of Science

    Most smoking cessation trials report efficacy of only one active medication versus placebo,1 with fewer reporting head-to-head comparisons of several active medications in the same trial.2 3 This leaves clinicians with the task of translating various reported and sometimes conflicting outcome data into reasonable treatment recommendations for patients. Piper and colleagues conducted a head-to-head study of two nicotine replacement therapies (NRTs) (patch and lozenge), bupropion, two combination therapies and placebo to provide empirical evidence for more informed clinical decisions. Their summary findings were that all the treatments studied were more effective than placebo and that combination lozenge plus patch therapy was superior to the other treatments. These findings are generally consistent with data reported in the most recent US Tobacco Dependence Clinical Practice Guideline,1 but data regarding the efficacy of the nicotine …

    View Full Text

    Footnotes

    • Competing interests DG has received research contracts to study smoking cessation therapies from Pfizer, Nabi Biopharmaceuticals, Sanofi-Aventis and Addex Pharmaceuticals; consulting fees and honoraria for speaking to groups about smoking cessation from Pfizer; consulting fees for protocol development from Evotec Neurosciences; and reimbursements for travel expenses and meeting registrations for attending meetings relating to smoking cessation from Pfizer. DG owns five shares of Pfizer stock.